Effects of melatonin on heart health in patients with cardiomyopathy
A Clinical Study to Assess the Cardioprotective Effects of Melatonin in Patients With Cardiomyopathy
This study tests if melatonin can help improve heart health in adults with cardiomyopathy while they continue their usual medications.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 46 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Tanta University Academic / other |
| Locations | 1 site (Dakahlia, Egypt, Mansoura) |
| Trial ID | NCT06846086 on ClinicalTrials.gov |
What this trial studies
This study evaluates the cardioprotective effects of melatonin in adult patients diagnosed with cardiomyopathy. Participants will receive either melatonin or a placebo while maintaining their standard cardiomyopathy medications. The research aims to assess melatonin's potential to improve cardiac function and mitigate myocardial injury through its antioxidant and anti-inflammatory properties. The study is designed to provide insights into a novel therapeutic strategy for a condition that currently has limited treatment options.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with a confirmed diagnosis of cardiomyopathy who are stable on standard medications.
Not a fit: Patients with severe kidney or liver impairment, recent hospitalization for cardiomyopathy exacerbation, or significant arrhythmias may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could offer a new treatment option that improves heart function and quality of life for patients with cardiomyopathy.
How similar studies have performed: Preliminary clinical studies have suggested that melatonin may improve cardiac function, indicating potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients (≥18 years) with a confirmed diagnosis of cardiomyopathy based on clinical, echocardiographic, or imaging findings. . * Stable condition on standard cardiomyopathy medications (e.g., ACE inhibitors, beta-blockers). * Ability to provide informed consent. Exclusion Criteria: * Recent hospitalization for cardiomyopathy exacerbation (within the last 3 months). * Severe kidney or liver impairment. * Use of other investigational drugs or antioxidants. * Pregnancy or planning to be pregnant in the next 6 months * Previous known hypersensitivity to melatonin. * Presence of atrial fibrillation or other significant arrhythmias at baseline. * Participation in another research.
Where this trial is running
Dakahlia, Egypt, Mansoura
- Mansoura University Hospital — Dakahlia, Egypt, Mansoura, Egypt (Recruiting)
Study contacts
- Study coordinator: Reem Alaa, Bachelor of Pharmacy (2023)
- Email: memoalaa19999@gmail.com
- Phone: +201124425525
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.